Journal of Gastrointestinal Surgery

, Volume 16, Issue 1, pp 68–79 | Cite as

Effect of Neoadjuvant Chemoradiation and Surgical Technique on Recurrence of Localized Pancreatic Cancer

  • Matthew H. G. KatzEmail author
  • Huamin Wang
  • Aparna Balachandran
  • Priya Bhosale
  • Christopher H. Crane
  • Xuemei Wang
  • Peter W. T. Pisters
  • Jeffrey E. Lee
  • Jean-Nicolas Vauthey
  • Eddie K. Abdalla
  • Robert Wolff
  • James Abbruzzese
  • Gauri Varadhachary
  • Xavier Chopin-Laly
  • Chusilp Charnsangavej
  • Jason B. Fleming
2011 SSAT Plenary Presentation



To determine the influence of neoadjuvant chemoradiation and standardized dissection of the superior mesenteric artery upon the oncologic outcome of patients with localized pancreatic adenocarcinoma.


One hundred ninety-four patients with pancreatic adenocarcinoma who underwent pancreaticoduodenectomy between 2004 and 2008 were evaluated. The retroperitoneal dissection was performed directly along the superior mesenteric artery in all cases. A standard histopathologic protocol that measured the “superior mesenteric artery (SMA) margin distance” between cancer cells and the superior mesenteric artery was employed.


Seventy-six percent of patients received neoadjuvant chemoradiation. The SMA margin was positive in 4% of patients but an additional 22% of patients with a negative margin had a SMA margin distance of ≤1 mm. Preoperative CT images overestimated the SMA margin distance in 73% of cases. Patients who received chemoradiation had longer SMA margin distances than those who did not. Patients who received chemoradiation and had a SMA margin of >1 mm had the lowest recurrence rates. Administration of neoadjuvant chemoradiation and lower estimated blood loss were independently associated with longer progression-free survival on multivariate analysis.


Preoperative chemoradiation and meticulous dissection of the superior mesenteric artery maximize the distance between cancer cells and the SMA margin and may influence locoregional control.


Pancreatic cancer Mesopancreas Chemoradiation Pancreaticoduodenectomy SMA margin Surgery 



We thank Henry Gomez, MD, manager of the Pancreatic Tumor Database at the University of Texas MD Anderson Cancer Center.


  1. 1.
    Iacobuzio-Donahue CA, Fu B, Yachida S et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. Journal of clinical oncology: Official Journal of the American Society of Clinical Oncology 2009; 27: 1806–1813.CrossRefGoogle Scholar
  2. 2.
    Sebag-Montefiore D, Stephens RJ, Steele R et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 2009; 373: 811–820.PubMedCrossRefGoogle Scholar
  3. 3.
    Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1986; 1: 1479–1482.PubMedCrossRefGoogle Scholar
  4. 4.
    Quirke P, Steele R, Monson J et al. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet 2009; 373: 821–828.PubMedCrossRefGoogle Scholar
  5. 5.
    Silberfein EJ, Kattepogu KM, Hu CY et al. Long-term survival and recurrence outcomes following surgery for distal rectal cancer. Ann Surg Oncol 2010; 17: 2863–2869.PubMedCrossRefGoogle Scholar
  6. 6.
    Hernandez JM, Morton CA, Al-Saadi S et al. The natural history of resected pancreatic cancer without adjuvant chemotherapy. The American surgeon 2010; 76: 480–485.PubMedGoogle Scholar
  7. 7.
    Sperti C, Pasquali C, Piccoli A, Pedrazzoli S. Recurrence after resection for ductal adenocarcinoma of the pancreas. World journal of surgery 1997; 21: 195–200.PubMedCrossRefGoogle Scholar
  8. 8.
    Oettle H, Post S, Neuhaus P et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA : the journal of the American Medical Association 2007; 297: 267–277.PubMedCrossRefGoogle Scholar
  9. 9.
    Klinkenbijl JH, Jeekel J, Sahmoud T et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Annals of Surgery 1999; 230: 776–782; discussion 782–774.Google Scholar
  10. 10.
    Katz MH, Merchant NB, Brower S et al. Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 trial. Ann Surg Oncol 2011; 18: 337–344.PubMedCrossRefGoogle Scholar
  11. 11.
    Evans DB, Rich TA, Byrd DR et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 1992; 127: 1335–1339.PubMedCrossRefGoogle Scholar
  12. 12.
    Evans DB, Varadhachary GR, Crane CH et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008; 26(21): 3496-3502.PubMedCrossRefGoogle Scholar
  13. 13.
    Katz MH, Pisters PW, Evans DB et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 2008; 206: 833–846; discussion 846–838.Google Scholar
  14. 14.
    Pisters PW, Abbruzzese JL, Janjan NA et al. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol 1998; 16: 3843–3850.PubMedGoogle Scholar
  15. 15.
    Varadhachary GR, Wolff RA, Crane CH et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008; 26(21):3487–3495.PubMedCrossRefGoogle Scholar
  16. 16.
    Gaedcke J, Gunawan B, Grade M et al. The mesopancreas is the primary site for R1 resection in pancreatic head cancer: relevance for clinical trials. Langenbeck's archives of surgery / Deutsche Gesellschaft fur Chirurgie 2010; 395: 451–458.Google Scholar
  17. 17.
    Raut CP, Tseng JF, Sun CC et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Annals of surgery 2007; 246: 52–60.PubMedCrossRefGoogle Scholar
  18. 18.
    Katz MH, Wang H, Fleming JB et al. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 2009; 16: 836–847.PubMedCrossRefGoogle Scholar
  19. 19.
    Gerard JP, Azria D, Gourgou-Bourgade S et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010; 28: 1638–1644.CrossRefGoogle Scholar
  20. 20.
    Hwang RF, Wang H, Lara A et al. Development of an integrated biospecimen bank and multidisciplinary clinical database for pancreatic cancer. Ann Surg Oncol 2008; 15: 1356–1366.PubMedCrossRefGoogle Scholar
  21. 21.
    Katz MH, Hwang R, Fleming JB, Evans DB. Tumor-node-metastasis staging of pancreatic adenocarcinoma. CA Cancer J Clin 2008; 58: 111–125.PubMedCrossRefGoogle Scholar
  22. 22.
    Varadhachary GR, Tamm EP, Abbruzzese JL et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 2006; 13: 1035–1046.PubMedCrossRefGoogle Scholar
  23. 23.
    Aloia TA, Lee JE, Vauthey JN et al. Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant therapy? J Am Coll Surg 2007; 204: 347–355.PubMedCrossRefGoogle Scholar
  24. 24.
    Yen TW, Abdalla EK, Pisters PW, Evans DB. Pancreaticoduodenectomy. In Von Hoff DD, Evans DB, Hruban RH (eds): Pancreatic cancer. Sudbury: Jones and Bartlett 2005; 265–286.Google Scholar
  25. 25.
    Exocrine pancreas. In Edge SB, Byrd DR, Compton CC et al. (eds): AJCC Cancer Staging Manual, 7th Edition. Chicago: Springer 2009; pp 241–249.Google Scholar
  26. 26.
    Exocrine pancreas. In Greene FL, Page DL, Fleming ID et al. (eds): AJCC Cancer Staging Manual, 6th Edition. Chicago: Springer 2002; 157–164.Google Scholar
  27. 27.
    Tseng JF, Raut CP, Lee JE et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract 2004; 8: 935–949; discussion 949–950.Google Scholar
  28. 28.
    Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics 1989; 45: 255–268.PubMedCrossRefGoogle Scholar
  29. 29.
    Chao YK, Yeh CJ, Chang HK et al. Impact of circumferential resection margin distance on locoregional recurrence and survival after chemoradiotherapy in esophageal squamous cell carcinoma. Ann Surg Oncol 2011; 18: 529–534.PubMedCrossRefGoogle Scholar
  30. 30.
    Wibe A, Rendedal PR, Svensson E et al. Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer. The British journal of surgery 2002; 89: 327–334.PubMedCrossRefGoogle Scholar
  31. 31.
    Gockel I, Domeyer M, Wolloscheck T et al. Resection of the mesopancreas (RMP): a new surgical classification of a known anatomical space. World journal of surgical oncology 2007; 5: 44.PubMedCrossRefGoogle Scholar
  32. 32.
    Winter JM, Cameron JL, Campbell KA et al. 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. Journal of Gastrointestinal Surgery: Official Journal of the society for Surgery of the Alimentary Tract 2006; 10: 1199–1210; discussion 1210–1191.Google Scholar
  33. 33.
    Neoptolemos JP, Stocken DD, Dunn JA et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Annals of surgery 2001; 234: 758–768.PubMedCrossRefGoogle Scholar
  34. 34.
    Baque P, Iannelli A, Delotte J et al. Division of the right posterior attachments of the head of the pancreas with a linear stapler during pancreaticoduodenectomy: vascular and oncological considerations based on an anatomical cadaver-based study. Surgical and radiologic anatomy : SRA 2009; 31: 13–17.PubMedCrossRefGoogle Scholar
  35. 35.
    Van den Broeck A, Sergeant G, Ectors N et al. Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2009; 35: 600–604.CrossRefGoogle Scholar
  36. 36.
    Pancreas (exocrine). In Pathologists CoA (ed) College of American Pathologists Cancer Protocols. 2009.Google Scholar
  37. 37.
    Verbeke CS, Menon KV. Variability in reporting resection margin status in pancreatic cancer. Annals of surgery 2008; 247: 716–717.PubMedCrossRefGoogle Scholar

Copyright information

© The Society for Surgery of the Alimentary Tract 2011

Authors and Affiliations

  • Matthew H. G. Katz
    • 1
    Email author
  • Huamin Wang
    • 2
  • Aparna Balachandran
    • 3
  • Priya Bhosale
    • 3
  • Christopher H. Crane
    • 4
  • Xuemei Wang
    • 5
  • Peter W. T. Pisters
    • 1
  • Jeffrey E. Lee
    • 1
  • Jean-Nicolas Vauthey
    • 1
  • Eddie K. Abdalla
    • 1
  • Robert Wolff
    • 6
  • James Abbruzzese
    • 6
  • Gauri Varadhachary
    • 6
  • Xavier Chopin-Laly
    • 1
  • Chusilp Charnsangavej
    • 3
  • Jason B. Fleming
    • 1
  1. 1.Department of Surgical OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Department of PathologyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  3. 3.Department of Diagnostic RadiologyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  4. 4.Department of Radiation OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  5. 5.Department of BiostatisticsThe University of Texas MD Anderson Cancer CenterHoustonUSA
  6. 6.Department of Gastrointestinal Medical OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations